Task: Explanation
Input (English): Paragraph: In January 2020, readers asked us about the accuracy of a story that claimed the U.S. Food and Drug Administration (FDA) had approved a new cocaine nasal spray for use as a local anesthetic. On Jan. 13, the cannabis and drug industry website Merry Jane published an article with the headline “A Cocaine Nasal Spray Just Received FDA Approval.” That article reported that: Medicinal cocaine has always been a thing, but now there’s an FDA-approved nasal spray aptly made with totally legal, pharmaceutical-grade white. On Monday, the pharmaceutical outfit Lannett Company announced that its new cocaine hydrochloride nasal spray product, dubbed Numbrino, cleared two Phase III, randomized, double-blind clinical trials. “The FDA’s approval of our cocaine HCl product, the first NDA approval to include full clinical trials in the company’s history, marks a major milestone in Lannett’s 70+ years of operations,” said Tim Crew, Lannett Company’s CEO, in a press release. “We believe the product has the potential to be an excellent option for the labeled indication. We expect to launch the product shortly …” The pharmaceutical company’s press release, also published on Jan. 13, read as follows: “Lannett Company, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway, for Cocaine Hydrochloride (HCl) Nasal Solution 4% (40 mg/mL), the company’s branded local anesthetic product … NUMBRINO® (cocaine hydrochloride) nasal solution is an ester local anesthetic indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults.” Claim: In January 2020, the Food and Drug Administration approved a nasal spray containing cocaine. 
Output (English): The press release, and Merry Jane’s article, were accurate. In a Jan. 10 letter addressed to Cody Laboratories, a subsidiary of the Philadelphia-headquartered Lannett, the FDA’s Center for Drug Evaluation and Research wrote: